COVID-19 Vaccine Development Update

July 9, 2020
Zydus has employed a multi pronged approach to combat the pandemic of Covid-19

**Diagnostic Products**
- Launched Covid-KAVACH ELISA tests under the technology transfer from ICMR
  - This test was found to have high sensitivity and specificity & also has the advantage of testing 90 samples together in a single run of 2.5 hours

**Wellness Products**
- We have preponed the launch of our sanitizer range under the Nycil brand which was originally planned for 2021
  - We did this in a record time and it has provided a great impetus to overall Zydus Wellness portfolio

**Prophylactic Vaccines**
- Our DNA Vaccine ZyCoV-D has undergone extensive pre-clinical studies and found to be safe, well tolerated and immunogenic.
  - Now, we plan to initiate the clinical trials for this DNA vaccine and fast track its registration

**Therapeutic Products**
- Contributed via vast supplies of HCQ and now Dexamethasone
  - Biological approach via long acting PEG-Interferon α-2b in India & Mexico. USFDA IND planned in Aug’ 20
  - Aim to launch Remdesivir (via licensing from Gilead) & Favipiravir

**NCEs**
- Received approval from COFERIS, Mexico to study Desidustat in the management of COVID-19
  - We will conduct a Phase 2b, for Desidustat in the Management of mild, moderate and severe COVID-19 patients

---

**Multi pronged approach to fight the pandemic of COVID-19**

**Diagnostic Products**
- Launched Covid-KAVACH ELISA tests under the technology transfer from ICMR

**Wellness Products**
- We have preponed the launch of our sanitizer range under the Nycil brand which was originally planned for 2021

**Prophylactic Vaccines**
- Our DNA Vaccine ZyCoV-D has undergone extensive pre-clinical studies and found to be safe, well tolerated and immunogenic.

**Therapeutic Products**
- Contributed via vast supplies of HCQ and now Dexamethasone
  - Biological approach via long acting PEG-Interferon α-2b in India & Mexico. USFDA IND planned in Aug’ 20
  - Aim to launch Remdesivir (via licensing from Gilead) & Favipiravir

**NCEs**
- Received approval from COFERIS, Mexico to study Desidustat in the management of COVID-19
  - We will conduct a Phase 2b, for Desidustat in the Management of mild, moderate and severe COVID-19 patients
Leveraging our capabilities in vaccine development and manufacturing, we fast-tracked the development of ZyCoV-D vaccine program.

**20+ years**
...of experience. started journey in 1998*

**Growth Driver**
...major growth driver for India geography*

**7**
Manufacturing (5) and R&D (2) Facilities*

**300+**
...dedicated scientists and Workforce*

**Current Strengths & Capabilities**

- **R&D**: Robust Product Pipeline coming out of dedicated R&D facilities in India & Europe. 2nd company in the world to develop Typhoid conjugate vaccines*
- **Capabilities** to conduct research from “Concept to First-in-man trials” under one roof across vaccines types - Live Attenuated
- Sub-unit
- DNA Vaccines
- Inactivated
- Inactivate Toxins

**Mfg. & Supply:**
- Dedicated manufacturing capabilities catering to differentiated portfolio*
- Vaccine innovation comes from two R&D centers focused on developing newer vaccines*
- Capacity to produce several Millions of doses. Aiming to build lean and agile supply chain

**Portfolio**: Focus on innovative and differentiated vaccines catering to unmet needs

---

**Portfolio**

**Zydu Vaccine Pipeline: Commercialized / Market Authorization Received**

<table>
<thead>
<tr>
<th>#</th>
<th>Vaccines</th>
<th>Pre-Clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Indian Market Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Measles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Tetanus toxoid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>DTap</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>MMR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Tetravalent Influenza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Typhoid polysaccharide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Conjugated Vaccine for Typhoid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Varicella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Anti-rabies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Tetanus (Adsorbed) I.P.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>MR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Pentavalexent (DTP-Hib-HepB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Hepatitis B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Tetanus-Diphtheria (Td)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>MMRV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>HPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Hepatitis A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Hepatitis E</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>ZyCoV-D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Team Analysis, Internal Data, Mfg. – Manufacturing, MA – Market Authorization, # In Market Vaccines
ZyCoV-D : Rapid Discovery and Product Development with strong Clinical and Regulatory Expertise

COVID-19 Sequence Published
Feb 2020
Zydus initiates fast-track discovery efforts using in-house DNA platform

Process & Formulation developed
Apr 2020

ZyCoV-D Animal studies
May 2020

With DCGI Permission we will initiate Phase I/II human clinical trials for ZyCoV-D which we aim to complete in three months and meet the regulator for their guidance

July 2020
ZyCoV-D Vaccine: A Novel Approach for COVID-19 Vaccine Development with favourable vaccine characteristics

**Benefits of DNA vaccine platform**

**Safety:**
- DNA Vaccines are non-infectious
- Carries no potential toxicity from viral vectors
- Minimum to no risk of vaccine enhanced diseases

**Efficacy and Boosting:**
- Stimulate both the humoral and cellular arms of the adaptive immune system
- DNA Vaccines pose minimal risk of anti-vector immunity and are efficacious

**Rapid and Scalable Manufacturing:**
- Ease of manufacturing related to minimal biosafety requirements (BSL-1)
- Rapid development from concept to human in 6 months
- Improved vaccine stability and lower cold chain requirements

Source: Daniel Wrapp et al. Science 2020;367:1260-1263
ZyCoV-D vaccine has successfully completed preclinical development and has received permission to initiate human clinical trials.

- In animal studies the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits.
- The antibodies produced by the vaccine were able to completely neutralize the wild type virus in virus neutralization assay indicating the protective potential of the vaccine candidate.
- No safety concerns were observed for the vaccine candidate in repeat dose toxicology studies by both intramuscular and intradermal routes of administration.
- In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic.
- Zydus has already manufactured clinical GMP batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India in over 1000 subjects.
The Phase I/II randomized, placebo-controlled, will evaluate the safety, tolerability, and immunogenicity of escalating dose levels of ZyCoV-D.
Key takeaways and next steps for ZyCoV-D

✓ DNA based vaccine
✓ Safety and Immunogenicity established in animal models
✓ Fast-track clinical development program being executed
✓ Large scale manufacturing planned to deliver millions of doses in 2020-21

✓ To cater huge demand of vaccine for frontline healthcare workers as well as general population in India and globally, we shall utilize,
  ➢ Our internal capacities and
  ➢ Leverage external partnerships to expand manufacturing capacities
Thank You

DISCLAIMER AND SAFE HARBOUR STATEMENT

THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF CADILA HEALTHCARE LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”).

The material that follows is a Presentation of general background information about the Company’s activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares.

This Presentation includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “may”, “will”, “seeks” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company’s intentions, beliefs and current expectations concerning, amongst other things, its results or operations, financial conditions, liquidity, prospects, growth, strategies and the industry in which the Company operates.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company’s actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment income (vi) cash flow projections etc.

The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates.

This document is just a Presentation and is not intended to be a “prospectus” or “offer document” or a “private placement offer letter” (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the Company’s equity shares. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company’s securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from.

This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This document and its contents should not be forwarded or delivered or transmitted in any manner to any person other than its intended recipient, and should not be reproduced in any manner whatsoever.